EUVIMEDEUVIMED entdecken
Klinische Studie (Phase I)Open Access

A Phase I Trial of Alpelisib Combined With Capecitabine in Patients With HER2-Negative Metastatic Breast Cancer

Danielle M File, Yara Abdou, Jeremy Force, Dominic T Moore, Carey K Anders, Katherine Reeder-Hayes, Lisa A Carey, Hyman B Muss, Charles M Perou, P Kelly Marcom, E Claire Dees

Clinical Breast Cancer · 2024

DOI: 10.1016/j.clbc.2024.08.001 ↗

Kurz gefasst

Klinische Studie (Phase I) in der Zeitschrift Clinical Breast Cancer, 2024. Verfasst von Danielle M File und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, The University of North Carolina at Chapel Hill, Chapel Hill, NC. Hauptthemen laut MEDLINE: Capecitabine, Breast Neoplasms, Antineoplastic Combined Chemotherapy Protocols, Erb-b2 Receptor Tyrosine Kinases. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, Del Mar Foundation, National Cancer Institute.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Alpelisib is an oral α-specific class I PI3K inhibitor approved in combination with fulvestrant for the treatment of PIK3CA-mutated hormone receptor-positive (HR+), human epidermal growth factor receptor 2 negative (HER2-) metastatic breast cancer. The tolerability of this drug with the oral chemotherapy capecitabine is unknown. PATIENTS AND METHODS: This phase I trial evaluated the dose-limiting toxicities (DLTs) and maximum tolerated dose (MTD) of alpelisib (250 mg or 300 mg daily for 3-weeks) with capecitabine (1000 mg/m2 twice daily for 2-weeks followed by a 1-week rest period) in patients with metastatic HER2-negative breast cancer, regardless of PIK3CA mutation status. RESULTS: Eighteen patients were treated with alpelisib-capecitabine. Half of the patients had HR+ breast cancer, and 16 had prior systemic therapy for metastatic disease. The MTD of alpelisib was 250 mg daily in combination with capecitabine 1000 mg/m2 twice daily. DLTs included hyperglycemia, QTc prolongation, fatigue, and chest pain. The most common grade 3 adverse event (AE) was hyperglycemia (28%). No grade 4 AEs were observed. Three patients discontinued therapy due to an AE. One-third of patients required dose reduction of both alpelisib and capecitabine. Four patients experienced a partial response and 8 patients experienced stable disease. The median progression-free survival was 9.7 months (95% CI 2.8-13.5 months) and median overall survival was 18.2 months (95% CI 7.2-35.2 months). Twelve patients had PIK3CA mutation testing completed, of these 2 had known or likely deleterious PIK3CA mutation. CONCLUSION: This study provides safety data for an oral combination therapy of alpelisib-capecitabine and defines tolerable doses for further study.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CapecitabineBreast NeoplasmsAntineoplastic Combined Chemotherapy ProtocolsErb-b2 Receptor Tyrosine KinasesMaximum Tolerated DoseHumansFemaleMiddle AgedAgedAdultQuinazolinesClass I Phosphatidylinositol 3-KinasesThiazoles

Stichwörter der Autor:innen

AlpelisibBreast cancerCapecitabinePI3KPIK3CA

Substanzen

CapecitabineErb-b2 Receptor Tyrosine KinasesQuinazolinesClass I Phosphatidylinositol 3-KinasesThiazolesAlpelisibERBB2 protein, humanPIK3CA protein, human

Autor:innen und Institutionen

  • Department of Medical Oncology, The University of North Carolina at Chapel Hill, Chapel Hill, NC.
  • Department of Medical Oncology, The University of North Carolina at Chapel Hill, Chapel Hill, NC; Lineberger Comprehensive Cancer Center, Chapel Hill, NC. Electronic address: Yara_Abdou@med.unc.edu.
  • Department of Medicine, Duke University, Durham, NC; Duke Cancer Institute, Durham, NC.
  • Lineberger Comprehensive Cancer Center, Chapel Hill, NC.
  • Department of Medical Oncology, The University of North Carolina at Chapel Hill, Chapel Hill, NC; Lineberger Comprehensive Cancer Center, Chapel Hill, NC.
  • Department of Medical Oncology, The University of North Carolina at Chapel Hill, Chapel Hill, NC; Lineberger Comprehensive Cancer Center, Chapel Hill, NC; Department of Genetics, The University of North Carolina, Chapel…

Förderung

  • NCI NIH HHS
  • Del Mar Foundation
  • National Cancer Institute
  • Novartis Pharmaceuticals Corp
  • John William Pope Foundation
  • Susan G. Komen

Zitieren

APA

File, D. M., Abdou, Y., Force, J., Moore, D. T., Anders, C. K., Reeder-Hayes, K., Carey, L. A., Muss, H. B., Perou, C. M., Marcom, P. K., & Dees, E. C. (2024). A Phase I Trial of Alpelisib Combined With Capecitabine in Patients With HER2-Negative Metastatic Breast Cancer. Clinical Breast Cancer. https://doi.org/10.1016/j.clbc.2024.08.001

Vancouver

File DM, Abdou Y, Force J, Moore DT, Anders CK, Reeder-Hayes K, et al. A Phase I Trial of Alpelisib Combined With Capecitabine in Patients With HER2-Negative Metastatic Breast Cancer. Clinical Breast Cancer. 2024. doi:10.1016/j.clbc.2024.08.001

BibTeX
@article{File2024,
  author = {File, Danielle M and Abdou, Yara and Force, Jeremy and Moore, Dominic T and Anders, Carey K and Reeder-Hayes, Katherine and Carey, Lisa A and Muss, Hyman B and Perou, Charles M and Marcom, P Kelly and Dees, E Claire},
  title = {A Phase I Trial of Alpelisib Combined With Capecitabine in Patients With HER2-Negative Metastatic Breast Cancer},
  journal = {Clinical Breast Cancer},
  year = {2024},
  doi = {10.1016/j.clbc.2024.08.001}
}
Kostenlos starten →